THE ARISING · EDITED READER EDITION
The Arising · November 8 Edited Reader Edition
This edited reader edition includes 2 reviewed articles from November 8, 2026. It is not the complete original issue. It includes 2 of the original 41 stories; 39 are not included here.
Longevity & Healthspan
Pelacarsen Lowered Lp(a) but Did Not Reduce Major Cardiovascular Events
A large randomized trial found a substantial change in the blood marker, without evidence of fewer events on its main clinical measure.
A better blood-test result is not always the same as better health. The Lp(a)HORIZON trial illustrates that distinction. Pelacarsen substantially lowered lipoprotein(a), or Lp(a), but did not reduce the trial’s combined measure of major cardiovascular events.
The Novartis-funded study randomly assigned 8,350 people who had cardiovascular disease and elevated Lp(a) to pelacarsen or placebo. The efficacy analysis included 8,322 participants, and median follow-up was 4.7 years. At 12 months, median Lp(a) was about 64 nmol/L in the pelacarsen group and 233 nmol/L in the placebo group.
The primary outcome, which combined cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization, occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group. The estimated hazard ratio was 1.02, with a 95% confidence interval from 0.90 to 1.15. The study also did not show a benefit on that composite among participants with higher starting Lp(a), at least 90 mg/dL.
The result concerns this treatment regimen, this study population, and this combined outcome. It does not establish that the groups had identical rates of each event separately. It does not establish that Lp(a) is harmless or answer whether another treatment, a different clinical population, or a longer follow-up would produce a different result. For a treatment meant to prevent illness, the key question remains whether changing the marker translates into better health, not just whether the number changes.
Original New England Journal of Medicine study by Cho and colleagues
Open this article on its own → Explore the related Living Magazine →
Longevity & Healthspan
A Trial Will Test Whether Two Medicines Preserve Everyday Physical Function
VITAL-H plans to test oral semaglutide and dapagliflozin separately against placebo in older adults. No results have been posted.
Standing up from a chair, walking steadily, and keeping your balance are everyday parts of independence. A registered trial will ask whether two existing medicines can help people preserve those abilities as they age.
The University of Texas Health Science Center at San Antonio plans to enroll 1,200 adults aged 60 to 75 in VITAL-H, a randomized, double-blind Phase 2b study. It will compare oral semaglutide, dapagliflozin, and placebo in three separate groups. The active medicines are not being tested together. The registry describes three years of treatment followed by six months of observation.
The study’s primary measure is the Short Physical Performance Battery, which combines tests of walking speed, standing balance, and repeated chair stands. Exercise capacity is a secondary measure. The study is designed to test physical function. It is not designed to establish whether either drug extends lifespan.
At the time of the November 8 issue, the November 6 registry entry listed the trial as not yet recruiting. The registry still supplied no results at editorial recheck. The enrollment figure is a target, not a count of people already enrolled. The eligibility criteria exclude people with diabetes and some other medical conditions, so any future findings will need to be interpreted in the population actually studied.
The noteworthy step is what the trial sets out to measure: abilities that matter in daily life rather than a laboratory marker alone. The trial registration is not evidence that either medication slows aging and is not a reason to start taking one for that purpose.
Open this article on its own → Explore the related Living Magazine →